Report Type
Single Stock Research Reports
Recent single stock reports highlight a recurring theme of solid top-line performance paired with aggressive strategic reinvestment, though varied operational headwinds are impacting near-term profitability across sectors. Veralto and Fluence Energy reported revenue largely in line with expectations, yet experienced contrasting margin outcomes; Veralto achieved a 24.6% operating margin beat, while Fluence's gross margins were compressed to 5.6% due to project-specific cost overruns. In the technology space, Alphabet’s massive AI build-out is reflected in 2026 Capex guidance of $175-185 billion, a shift that is forcing analysts to abandon free cash flow yield in favor of P/E and EBITDA valuation frameworks. Growth outlooks remain cautious, with Match Group signaling softer 2026 revenue due to regulatory costs and Veralto projecting moderate sales growth between LSD+ and MSD+. Macroeconomic risks are also tempering sentiment, as evidenced by downgrades for Harbour Energy driven by anticipated 2026 LNG oversupply and high leverage. Collectively, these reports underscore a market environment where robust demand and backlogs, such as Fluence’s $5.5 billion, must be weighed against rising capital intensity and shifting valuation metrics.
578 reports available
All reports
Page 22 of 24
Cameco Corp: Flooding Causes Production Disruption
Goldman Sachs · May 11, 2026
Auto1 Group: April 2026 High Frequency Data Update
Goldman Sachs · May 11, 2026
YOFC New Procurement Tender Released
Goldman Sachs · May 11, 2026
Vontier Corp: Lowering Estimates on Slower Start to the Year
Goldman Sachs · May 11, 2026
Deutsche Bank Updating Estimates Post Q1 2026
Goldman Sachs · May 11, 2026
Arxis Company Analysis and Buy Initiation
Goldman Sachs & Co. LLC · May 11, 2026
Molina Healthcare Analyst Day Recap
Goldman Sachs · May 11, 2026
User Terminal in Expansion
Goldman Sachs · May 11, 2026
F3Q26 Takeaways: A Solid Quarter With Steps Towards an Acceleration in Profitability
Goldman Sachs · May 11, 2026
Evaluating Execution Risk for Avexitide Phase 3 Readout in Post-Bariatric Hypoglycemia
Goldman Sachs · May 11, 2026
NCR Voyix 1Q26 Takeaways
Goldman Sachs · May 11, 2026
Vodacom Mixed FY26 Results Reassuring on South African Growth
Goldman Sachs · May 11, 2026
CSL First Take FY26 Trading Downgrade
Goldman Sachs · May 11, 2026
Elia Group Structurally Compelling
Goldman Sachs · May 11, 2026
Fidelity National Information Services 1Q26 Takeaways
Goldman Sachs · May 11, 2026
BinDawood Holding 1Q26 Earnings First Take
Goldman Sachs · May 11, 2026
Cenomi Centers 1Q26 Earnings Call Takeaways
Goldman Sachs · May 11, 2026
Bath & Body Works Promotional Activity Update
Goldman Sachs · May 11, 2026
Incyte Corp Management Meeting Frames Revenue-Replacement Strategy
Goldman Sachs · May 11, 2026
Looking for R&D Levers
Goldman Sachs · May 11, 2026
Upwork Q1 2026 Review
Goldman Sachs · May 11, 2026
Nemetschek: Growth Momentum Continues in Core Segments
Goldman Sachs · May 11, 2026
Prototype Testing and Timeline Movement
Goldman Sachs · May 11, 2026
MetaX GPU Ramp Up and 1Q26 Earnings Update
Goldman Sachs · May 11, 2026